Overall Status

Active, not recruiting (1)

Completed (1)

Recruiting (1)

Phase

phase 1 (2)

phase 2/phase 3 (1)

Sponsor

National Cancer Institute (NCI) (3)

Collaborator

NRG Oncology (1)

Intervention

cetuximab (3)

laboratory biomarker analysis (3)

intensity-modulated radiation therapy (2)

atezolizumab (1)

cisplatin (1)

docetaxel (1)

ipilimumab (1)

lenalidomide (1)

quality-of-life assessment (1)

Study Documents

Intervention Type

biological (3)

other (3)

drug (2)

radiation (2)

Funder Type

NIH (3)

Study Type

Interventional (3)

stage iva laryngeal squamous cell carcinoma ajcc v7

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III

Recruiting

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
+16 more

Atezolizumab
+6 more

Birmingham, Alabama
+289 more

Jan 31, 2023

Active, not recruiting

Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
+8 more

Cetuximab
+3 more

Pittsburgh, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI)

Jan 26, 2023

Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma Trial

Completed

Recurrent Colon Carcinoma
+41 more

Cetuximab
+2 more

Columbus, Ohio

Ohio State University Comprehensive Cancer Center

Mar 12, 2020